Anti-human immunodeficiency virus type 1 agent alpha-hydroxy glycineamide enters the target cells via a mechanism of passive diffusion.

about

Anti-human immunodeficiency virus type 1 agent alpha-hydroxy glycineamide enters the target cells via a mechanism of passive diffusion.

Item

http://www.wikidata.org/entity/Q39000386

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Anti-human immunodeficiency vi ...... echanism of passive diffusion.

@en

Anti-human immunodeficiency vi ...... echanism of passive diffusion.

@nl

type

Item

label

Anti-human immunodeficiency vi ...... echanism of passive diffusion.

@en

Anti-human immunodeficiency vi ...... echanism of passive diffusion.

@nl

prefLabel

Anti-human immunodeficiency vi ...... echanism of passive diffusion.

@en

Anti-human immunodeficiency vi ...... echanism of passive diffusion.

@nl

P1476

Anti-human immunodeficiency vi ...... mechanism of passive diffusion

@en

P2093

Anders Vahlne

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein

GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway.

Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Tripeptide interference with human immunodeficiency virus type 1 morphogenesis.

Isolation and characterization of a small antiretroviral molecule affecting HIV-1 capsid morphology.

Cellular pharmacokinetics and pharmacodynamics of dipyridamole in vascular smooth muscle cells.

Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide

Selected amino acid substitutions in the C-terminal region of human immunodeficiency virus type 1 capsid protein affect virus assembly and release.

Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before transport across the intestinal epithelium.

P304

1388-1393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JPHP.12269

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Masoud Youssefi

P577

2014-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24780097

http://www.w3.org/2001/XMLSchema#string